Fresenius SE KGaA (XSWX:FRE) ROCE %: 7.21% (As of Mar. 2026)


XSWX:FRE Fresenius SE & Co KGaA XSWX:FRE
71 GF Score
Price CHF35.86
GF Value CHF32.85
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Fresenius SE KGaA ROCE %?

Fresenius SE KGaA XSWX:FRE 71 ROCE % is 7.21% as of Mar. 2026. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF32.85 (Fairly Valued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fresenius SE KGaA's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.21%.

Fresenius SE KGaA  (XSWX:FRE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fresenius SE KGaA ROCE % Related Terms

Fresenius SE KGaA ROCE % Historical Data

* Premium members only.

The historical data trend for Fresenius SE KGaA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fresenius SE KGaA ROCE % Chart

Fresenius SE KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.61 3.16 2.54 6.31 7.79

Fresenius SE KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.03 6.54 5.64 11.16 7.21
XSWX:FRE
71GF Score
Fresenius SE & Co KGaA XSWX:FRE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fresenius SE KGaA ROCE % Calculation

Fresenius SE KGaA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=2456.953/( ( (40658.827 - 8410.916) + (38627.255 - 7822.497) )/ 2 )
=2456.953/( (32247.911+30804.758)/ 2 )
=2456.953/31526.3345
=7.79 %

Fresenius SE KGaA's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=2188.056/( ( (38627.255 - 7822.497) + (38564.047 - 8680.324) )/ 2 )
=2188.056/( ( 30804.758 + 29883.723 )/ 2 )
=2188.056/30344.2405
=7.21 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.21% mean?
Fresenius SE KGaA (XSWX:FRE) has a ROCE % of 7.21% as of Mar. 2026.
Is Fresenius SE KGaA's ROCE % too high?
Fresenius SE KGaA's current ROCE % is 7.21%. The Healthcare Providers & Services industry median ROCE % is 6.41. Fresenius SE KGaA's value of 7.21% is 12.5% above this industry median. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's ROCE % compare to HCA and THC?
Fresenius SE KGaA's ROCE % of 7.21% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Fresenius SE KGaA's value of 7.21% is 12.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current ROCE % of 7.21% is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current ROCE % is 7.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF32.85, compared to a current price of CHF35.86 — trading 9.2% above its estimated fair value. The current ROCE % is 7.21% and 12.5% above the Healthcare Providers & Services industry median of 6.41. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current ROCE % is 7.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued. The current stock price of CHF35.86 is trading 9.2% above its estimated GF Value™ of CHF32.85. GuruFocus considers Fresenius SE KGaA to be Fairly Valued.

Key valuation signals for XSWX:FRE:

  • ROCE %: 7.21%
  • GF Value™: CHF32.85 vs. price of CHF35.86 (9.2% above fair value)
  • GF Score™: 71/100 with 5 warning signs
  • Industry Position: 12.5% above the Healthcare Providers & Services median

No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fresenius SE KGaA Business Description

Address Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score

Get the complete analysis for XSWX:FRE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF35.86
Price
CHF32.85
GF Value